文献速递肝病消化道肿瘤与早癌

Galectin-4驱动肝细胞癌抗PD-L1/BVZ耐药机制

Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma.
PubMed 文献 · Gut · 2025-10-07

该研究通过单细胞RNA测序和前瞻性临床队列(NCT04649489)发现,基线血清galectin-4升高与肝细胞癌ATZ/BVZ耐药及不良预后相关。Galectin-4通过抑制LDHA蛋白酶体降解增强糖酵解,放大HIF-1α介导的CXCL6表达,促进代谢适应和免疫抑制微环境。遗传敲低或药理抑制galectin-4可逆转耐药。

要点

  • 基线血清galectin-4升高与ATZ/BVZ耐药及不良预后相关
  • Galectin-4通过LDHA/HIF-1α/CXCL6轴驱动代谢适应和免疫排斥
  • 靶向galectin-4可恢复ATZ/BVZ敏感性,并可作为预测生物标志物

核心结论

  • Galectin-4/LDHA/HIF-1α/CXCL6轴激活在ATZ/BVZ耐药中起关键作用,galectin-4是有前景的治疗靶点和预测生物标志物。

研究设计与样本

  • 研究采用单细胞RNA测序和前瞻性临床队列(NCT04649489)识别与ATZ/BVZ耐药相关的基因。
  • 构建多种临床前HCC模型和共培养系统,并使用飞行时间流式细胞术探索分子机制。

主要发现

  • 基线血清galectin-4水平升高与ATZ/BVZ治疗耐药及不良预后相关。
  • Galectin-4过表达通过促进代谢适应和免疫抑制微环境使ATZ/BVZ疗效失效,表现为CD8+ T细胞浸润减少和细胞毒性受损及PD-L1+肿瘤相关中性粒细胞积聚。
  • Galectin-4通过竞争性减少TRIM28结合抑制LDHA蛋白酶体降解,增强糖酵解并放大HIF-1α介导的CXCL6表达。
  • 遗传敲低或药理抑制galectin-4可逆转代谢适应和免疫排斥,恢复临床前模型对抗PD-L1/BVZ治疗的敏感性。

临床怎么用

  • 基线血清galectin-4或可作为HCC患者ATZ/BVZ治疗反应的预测生物标志物。
  • 靶向galectin-4联合抗PD-L1/BVZ可能改善耐药HCC的治疗效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combination of atezolizumab and bevacizumab (ATZ/BVZ) therapy has significantly advanced therapeutic approaches for hepatocellular carcinoma (HCC). However, less than 30% of patients achieve durable responses, highlighting the urgent need to understand mechanisms underlying resistance. OBJECTIVE: This study aimed to elucidate the mechanisms of resistance to ATZ/BVZ therapy in HCC and identify druggable targets associated with resistance, thus improving the treatment efficacy of ATZ/BVZ-resistant HCC. DESIGN: We employed single-cell RNA sequencing and a prospective clinical cohort (NCT04649489) to identify and characterise potential genes that contribute to ATZ/BVZ therapy resistance. Multiple preclinical HCC models and a coculture system were constructed, and cytometry by time-of-flight technology was used to further explore the relevant molecular mechanism. RESULTS: Elevated baseline serum galectin-4 levels correlated with resistance to ATZ/BVZ therapy and unfavourable prognosis in HCC. Galectin-4 overexpression nullified ATZ/BVZ therapy efficacy through promoting metabolic adaptation and fostering an immunosuppressive tumour microenvironment characterised by reduced infiltration and impaired cytotoxicity of CD8+ T cells and accumulation of PD-L1+ tumour-associated neutrophils. Mechanistically, galectin-4 inhibited proteasomal degradation of lactate dehydrogenase A (LDHA) by competitively decreasing tripartite motif containing 28 binding, thereby enhancing glycolysis and amplifying HIF-1α-mediated C-X-C motif chemokine ligand 6 (CXCL6) expression. Genetic knockdown or pharmacological inhibition of galectin-4 reversed metabolic adaptation and immune exclusion, and restored sensitivity to anti-PD-L1/BVZ therapy in preclinical models. CONCLUSION: Activation of the galectin-4/LDHA/HIF-1α and CXCL6 axis plays a pivotal role in ATZ/BVZ therapy resistance. Galectin-4 serves as a promising therapeutic target to improve immunotherapy efficacy and an effective predictive biomarker for immunotherapy response in HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Xu W, Zhao Y, Weng J, et al. Galectin-4 drives anti-PD-L1/BVZ resistance by regulating metabolic adaptation and tumour-associated neutrophils in hepatocellular carcinoma. Gut. 2025. PMID: 41057233. doi:10.1136/gutjnl-2025-336374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。